Viking Therapeutics(VKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VKTX Viking Therapeutics

Not Yet Opened 02-04 16:00:00 EST

29.56

+0.15

+0.51%

盘后29.22

-0.34-1.15%

19:56 EST

High29.66	Low28.01	Vol3.21M
Open29.53	D1 Closing29.41	Amplitude5.59%
Mkt Cap3.34B	Tradable Cap3.25B	Total Shares113.04M
T/O93.16M	T/O Rate2.92%	Tradable Shares109.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics","latestPrice":29.56,"timestamp":1770238800000,"preClose":29.41,"halted":0,"volume":3214352,"hourTrading":{"tag":"盘后","latestPrice":29.22,"preClose":29.56,"latestTime":"19:56 EST","volume":24280,"amount":715620.0216,"timestamp":1770252966853,"change":-0.34,"changeRate":-0.011502,"amplitude":0.028417},"delay":0,"changeRate":0.005100306018361053,"floatShares":109980302,"shares":113036344,"eps":-2.119536,"marketStatus":"Not Yet Opened","change":0.15,"latestTime":"02-04 16:00:00 EST","open":29.53,"high":29.655,"low":28.01,"amount":93158558.59687999,"amplitude":0.055933,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.119536,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770282000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1430280000000,"exchange":"NASDAQ","adjPreClose":29.41,"preHourTrading":{"tag":"盘前","latestPrice":29.53,"preClose":29.41,"latestTime":"09:29 EST","volume":24639,"amount":730713.229947,"timestamp":1770215350235,"change":0.12,"changeRate":0.00408,"amplitude":0.026862},"postHourTrading":{"tag":"盘后","latestPrice":29.22,"preClose":29.56,"latestTime":"19:56 EST","volume":24280,"amount":715620.0216,"timestamp":1770252966853,"change":-0.34,"changeRate":-0.011502,"amplitude":0.028417},"volumeRatio":1.13771,"impliedVol":0.7888,"impliedVolPercentile":0.216},"requestUrl":"/m/hq/s/VKTX","defaultTab":"news","newsList":[{"id":"2609318265","title":"Viking Therapeutics Inc. published an update to their financial calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2609318265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609318265?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:08","pubTimestamp":1770239305,"startTime":"0","endTime":"0","summary":"Viking Therapeutics Inc. will report financial results for the fourth quarter and year-end 2025 after the market closes on February 11, 2026. The results will be released on the company's website. A conference call to discuss the results and provide general corporate updates will be held on February 11, 2026, at 4:30 p.m. Eastern Time. The call can be accessed live via the internet by visiting the Webcasts page of Viking's website. An archive of the webcast will be available on the same page for 30 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on February 04, 2026, and is solely responsible for the information contained ther","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL2kwF9d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VKTX","BK4588","BK4585","BK4599"],"gpt_icon":0},{"id":"2608980980","title":"Obesity Drugmakers and Developers Fall After Rival Novo Nordisk Warns of Steep 2026 Sales Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2608980980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608980980?lang=en_us&edition=fundamental","pubTime":"2026-02-04 01:33","pubTimestamp":1770140018,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"bcb73b9a2718796b6bdfcc143da1014d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ177:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","LU2112291526.USD","BK4139","BK4534","LU0868494617.USD","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4599","IE00B4R5TH58.HKD","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD","LU0122379950.USD","IE00B2B36J28.USD","BK4588","AMGN","LU0058720904.USD","IE00BJT1NW94.SGD","LU1571399168.USD","LU2468319806.SGD","BK4533","LU0289739699.SGD","IE0002141913.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","BK4585","LU0889565916.HKD","IE0009355771.USD","BK4007","LU2242646821.SGD","VKTX","LU0320765992.SGD","LU1983299246.USD","SG9999001440.SGD","LU0109394709.USD","BK4581","BK4566"],"gpt_icon":0},{"id":"2608809553","title":"Structure Therapeutics Down 5.3%, Viking Therapeutics Down 3.3%, Amgen Down 1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608809553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608809553?lang=en_us&edition=fundamental","pubTime":"2026-02-04 01:33","pubTimestamp":1770140018,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ177:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4566","LU1571399168.USD","IE0009355771.USD","LU2242652126.USD","IE00BJJMRZ35.SGD","BK4599","LU0058720904.USD","LU2468319806.SGD","BK4585","LU0320765992.SGD","LU2242646821.SGD","LU1061106388.HKD","LU1057294990.SGD","BK4534","BK4139","LU0868494617.USD","IE00B4R5TH58.HKD","LU0122379950.USD","LU2089984988.USD","LU0289739699.SGD","BK4007","IE00BJT1NW94.SGD","AMGN","LU0889565916.HKD","IE00BFTCPJ56.SGD","LU1983299246.USD","IE0002141913.USD","LU0109394709.USD","LU2112291526.USD","IE00B2B36J28.USD","VKTX","LU1023059063.AUD","SG9999001440.SGD","BK4581","GPCR","BK4588","BK4533"],"gpt_icon":0},{"id":"2608137818","title":"Viking Therapeutics stellt neue klinische Fortschritte bei Medikamenten gegen Adipositas und Stoffwechselkrankheiten vor","url":"https://stock-news.laohu8.com/highlight/detail?id=2608137818","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608137818?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:37","pubTimestamp":1770068231,"startTime":"0","endTime":"0","summary":"Viking Therapeutics Inc. hat eine Prsentation verffentlicht, in der aktuelle Fortschritte in der Entwicklung neuartiger Therapeutika für metabolische und endokrine Erkrankungen vorgestellt werden. Zu den Schwerpunkten zhlen das Phase-3-Programm mit dem dualen GLP-1/GIP-Agonisten VK2735 zur Behandlung von Adipositas, positive Phase-2b-Daten zum selektiven Schilddrüsenhormonrezeptor-β-Agonisten VK2809 bei MASH sowie erfolgreiche Phase-1b-Daten für VK0214 bei X-ALD. Darüber hinaus wurde für einen Amylin-Agonisten ein IND-Antrag für das erste Quartal 2026 angekündigt. Die vollstndige Prsentation knnen Sie über den untenstehenden Link abrufen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL6XhSgz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4139","VKTX","BK4588","BK4585"],"gpt_icon":0},{"id":"2607467117","title":"Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), Viking Therapeutics (VKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607467117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607467117?lang=en_us&edition=fundamental","pubTime":"2026-01-29 01:20","pubTimestamp":1769620821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on GH Research (GHRS – Research Report), Viking Therape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-gh-research-ghrs-viking-therapeutics-vktx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-gh-research-ghrs-viking-therapeutics-vktx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","VKTX","BK4535","LABU","BK4007","BK4581","BK4139","BK4585","BK4588","BK4599","BK4551","BK4196","BK4112","XBI","GHRS","BK4137","LU0029874061.USD","BK4539"],"gpt_icon":0},{"id":"2606207202","title":"Viking Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Neil William Aubuchon","url":"https://stock-news.laohu8.com/highlight/detail?id=2606207202","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606207202?lang=en_us&edition=fundamental","pubTime":"2026-01-27 08:56","pubTimestamp":1769475391,"startTime":"0","endTime":"0","summary":"Viking Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Neil William Aubuchon as the beneficial owner, serving as Chief Commercial Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL89RGVd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Viking Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Neil William Aubuchon","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4585","BK4588","VKTX","BK4139"],"gpt_icon":0},{"id":"2603642839","title":"Viking Therapeutics Showcases Advancements in Obesity and Metabolic Disease Pipeline in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603642839","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603642839?lang=en_us&edition=fundamental","pubTime":"2026-01-15 05:16","pubTimestamp":1768425368,"startTime":"0","endTime":"0","summary":"Viking Therapeutics Inc. has released a corporate presentation detailing progress across its pipeline of metabolic and endocrine disease therapeutics. Key highlights include the ongoing Phase 3 VANQUISH program evaluating VK2735, a dual GLP-1/GIP agonist for obesity, and the successful completion of the Phase 2a VENTURE Oral study for the tablet formulation of VK2735, which achieved its primary endpoint. The company also reported positive Phase 2b data for VK2809 in MASH and successful Phase 1b results for VK0214 in X-ALD. An investigational new drug application for an amylin agonist targeting obesity is planned for the first quarter of 2026. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL5drCtY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","BK4139","BK4585","BK4588","BK4599"],"gpt_icon":0},{"id":"2603816527","title":"Appetite for weight-loss deals broader than visible, Viking CEO says","url":"https://stock-news.laohu8.com/highlight/detail?id=2603816527","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603816527?lang=en_us&edition=fundamental","pubTime":"2026-01-13 08:15","pubTimestamp":1768263326,"startTime":"0","endTime":"0","summary":"Appetite for weight-loss deals broader than visible, Viking CEO saysBy Puyaan SinghJan 12 (Reuters) - Weight-loss drug developer Viking Therapeutics VKTX.O CEO said on Monday that strategic interest i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL4N3YD1YL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","IE00BDCRKT87.USD","LU0321505868.SGD","LU1162221912.USD","LU0170899867.USD","LU2054465674.USD","IE00BLSP4239.USD","SG9999003800.SGD","LU2505996509.AUD","LU1551013425.SGD","LU1366192091.USD","LU1064131342.USD","LU1917777945.USD","LU1974910355.USD","LU1119994496.HKD","LU2746668974.SGD","LU1670628061.USD","LU2592432038.USD","LU1988902786.USD","LU0289739699.SGD","SG9999013999.USD","IE0002270589.USD","LU0265550946.USD","LU0976567544.SGD","LU2505996681.GBP","LU1057294990.SGD","IE00B1XK9C88.USD","LU0267386448.USD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU0640476718.USD","LU0683600562.USD","LU2023250504.SGD","VKTX","IE00BWXC8680.SGD","BK4007","BK4504","LU1496350502.SGD","LU2237443382.USD","LU2357305700.SGD","LU0203345920.USD","LU2430703095.HKD","LU0306806265.USD","LU0320765489.SGD","LU2237443622.USD","IE00B3S45H60.SGD","SG9999001176.USD","IE00B775SV38.USD","IE00BBT3K403.USD","LU2552382132.HKD","LU1267930490.SGD","LU1066051498.USD","LU0211326839.USD","LU0225771236.USD","LU0820562030.AUD","LU2237443549.SGD","IE00BYXW3230.USD","LU0345769128.USD","LU0820561909.HKD","LU2211815571.USD","SG9999011175.SGD","LU0868494708.USD","BK4588","LU0215105999.USD","LU0787776722.HKD","LU0417517546.SGD","LU1116320901.HKD","LU2756315664.SGD","LU0211326755.USD","LU2552382215.SGD","IE00BHPRN162.USD","LU0323591593.USD","BK4516","BK4581","LU1244550221.USD","IE00B19Z3B42.SGD","LU0306807586.USD","IE00BKVL7J92.USD","LU1720051017.SGD","BK4566","BK4534","BK4207","LU1894683348.USD","LU1023059063.AUD","LU1670627923.USD","LU1914381329.SGD","LU0211328371.USD","LU2552382058.USD","BK4550","LU0820561818.USD","LU0496365809.HKD","LU2462157665.USD","LU0234572021.USD","IE0034235303.USD","IE0034235295.USD","LU0251132253.USD","LU1244550577.SGD","LU0256863811.USD","LU0345769631.USD","LU1363072403.SGD","LU1894683264.USD","LU0882574139.USD","LU1244550494.USD","LU0689472784.USD","IE00B1BXHZ80.USD","LU0203347892.USD","BK4585","LU0943347566.SGD","IE000M9KFDE8.USD","LU2237443895.HKD","IE00BFXG1179.USD","IE00BJLML261.HKD","LU1084165304.USD","SG9999002232.USD","LU0208291251.USD","LU2106854487.HKD","LU2242649171.HKD","LU2430703178.SGD","LU0211331839.USD","LU0211327993.USD","LU0971096721.USD","LU0942090050.USD","SGXZ57979304.SGD","LU0122379950.USD","LU2213496289.HKD","LU2381873111.SGD","LU2237443978.SGD","LU1116320737.USD","LU0070302665.USD","LU0225284248.USD","LU0985481810.HKD","LU0106831901.USD","LU2023250843.SGD","LU2237443465.HKD","LU0149725797.USD","LU0310799852.SGD","BK4139","LU2417539215.USD","LU1883839398.USD","IE00BN8TJ469.HKD","LU0265550359.USD","LU0320765646.SGD","LU2456880835.USD","LU0345770993.USD","BK4568","SG9999002224.SGD","IE00BLSP4452.SGD","BK4592","LU0456855351.SGD","LU1551013342.USD","LU2023250330.USD","LU2756315318.SGD","LU0048584097.USD","IE0034235188.USD","LU1066053197.SGD","LU1496350171.SGD","IE00BJTD4N35.SGD","LU0964807845.USD","IE00BJTD4V19.USD","LU1629891620.HKD","LU1668664300.SGD","LU0058720904.USD","LU2236285917.USD","LU1145028129.USD","IE00BDRTCR15.USD","SG9999001176.SGD","IE00BKDWB100.SGD","LU0106261372.USD","LU2264538146.SGD","LU2430703251.USD","LU0345770308.USD","LU0321505439.SGD","LU1280957306.USD","IE00B19Z3581.USD","LU2746668461.USD","LU0238689110.USD","LU1261432733.SGD","LU1032466523.USD","LU0006306889.USD","LU0868494617.USD","BK4533","LU1720051108.HKD"],"gpt_icon":0},{"id":"2602851415","title":"Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851415","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851415?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:02","pubTimestamp":1768219379,"startTime":"0","endTime":"0","summary":"Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL5TgZPP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","BK4599","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2602514527","title":"Viking Therapeutics Announces Publication of Results From Phase 2 Venture Trial of Dual Glp-1/Gip Receptor Agonist Vk2735 in the Journal Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514527?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA4FJFXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VKTX","BK4599","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2602713993","title":"Viking Therapeutics (VKTX) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2602713993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602713993?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:55","pubTimestamp":1767966957,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Naz Rahman reiterated a Buy rating on Viking Therapeutics yesterday and set a price target of $70.00. The company’s shares clos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/viking-therapeutics-vktx-receives-a-buy-from-maxim-group-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/viking-therapeutics-vktx-receives-a-buy-from-maxim-group-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4599","VKTX","BK4585"],"gpt_icon":0},{"id":"2602373512","title":"Viking Therapeutics: Timely VK2735 Clinical Progress and Flexible Dosing Drive Favorable Risk‑Reward and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373512","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602373512?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:15","pubTimestamp":1767960954,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward Nash from Canaccord Genuity mainta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/viking-therapeutics-timely-vk2735-clinical-progress-and-flexible-dosing-drive-favorable-risk‑reward-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/viking-therapeutics-timely-vk2735-clinical-progress-and-flexible-dosing-drive-favorable-risk‑reward-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","VKTX"],"gpt_icon":0},{"id":"2602963163","title":"Positioning Viking Therapeutics’ VK2735 as a Differentiated, Best-in-Class Obesity Franchise with Compelling Monthly Maintenance Potential Supporting a Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602963163","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602963163?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:46","pubTimestamp":1767887183,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh has maintained their bullish stance on VKTX stock, giving a Buy rating today. Andy Hsieh has given his Buy rating ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positioning-viking-therapeutics-vk2735-as-a-differentiated-best-in-class-obesity-franchise-with-compelling-monthly-maintenance-potential-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positioning-viking-therapeutics-vk2735-as-a-differentiated-best-in-class-obesity-franchise-with-compelling-monthly-maintenance-potential-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VKTX"],"gpt_icon":0},{"id":"2601366472","title":"Viking Therapeutics Completes Enrollment for VK2735 Obesity Maintenance Dosing Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366472","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366472?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:01","pubTimestamp":1767873698,"startTime":"0","endTime":"0","summary":"Viking Therapeutics Inc. announced the completion of patient enrollment in its exploratory maintenance dosing clinical trial of VK2735 for obesity. VK2735 is a dual agonist of the GLP-1 and GIP receptors, being developed in both oral and subcutaneous formulations for the treatment of metabolic disorders such as obesity. The Phase 1 study is evaluating various maintenance dosing regimens—including subcutaneous and oral administration—following initial weight loss achieved with weekly VK2735 treatment. Approximately 180 adults with obesity have been enrolled. Results from this study are expected to be reported later this year. In addition, Viking is conducting two Phase 3 trials  to assess the efficacy and safety of subcutaneous VK2735 in adults with obesity or overweight, with or without type 2 diabetes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL7lNvG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","BK4599","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2601366195","title":"Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of Vk2735 in Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366195?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA6C46SK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4139","VKTX","BK4588","BK4585"],"gpt_icon":0},{"id":"2601832336","title":"Will Viking Therapeutics’ New CCO Reframe VKTX’s Obesity Strategy Amid Intensifying GLP-1 Competition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601832336","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601832336?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:21","pubTimestamp":1767824478,"startTime":"0","endTime":"0","summary":"Viking Therapeutics has appointed industry veteran Neil Aubuchon as chief commercial officer and is preparing to highlight its late-stage obesity and liver disease programs at the upcoming J.P. Morgan Healthcare Conference, underscoring a shift toward commercialization in the cardiometabolic arena.\nAt the same time, intensifying competition and pricing moves in the obesity-drug market are pressuring expectations for Viking’s VK2735 program, making its new commercial leadership especially...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/will-viking-therapeutics-new-cco-reframe-vktxs-obesity-strat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/will-viking-therapeutics-new-cco-reframe-vktxs-obesity-strat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2357125470.USD","GLP","LU2506951792.HKD","BK4599","BK4585","BK4144","CCO","BK4588","BK4009","VKTX","LU0823414551.USD","LU2249611893.SGD","LU2294711713.HKD","BK4139","BK4590","LU0823414478.USD"],"gpt_icon":0},{"id":"1146401006","title":"Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146401006","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146401006?lang=en_us&edition=fundamental","pubTime":"2026-01-07 23:15","pubTimestamp":1767798955,"startTime":"0","endTime":"0","summary":"Weight-loss drugmakers' stocks jumped on Wednesday. Structure Therapeutics up 5%; Eli Lilly rose 4% to record high; Amgen up 3%; Roche, Novo up around 2%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Weight-Loss Drugmakers' Stocks Jump. Eli Lilly Rises 4% to Record High","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","RHHBY","PFE","AMGN","VKTX","NVO","GPCR"],"gpt_icon":0},{"id":"2601371870","title":"Press Release: Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601371870","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601371870?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787200,"startTime":"0","endTime":"0","summary":"Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise. SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMN","BK4196","VKTX","BK4588","BK4139","BK4585","BK4599"],"gpt_icon":0},{"id":"1123730705","title":"Weight-Loss Drugmakers' Stocks Jump. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up Around 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123730705","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123730705?lang=en_us&edition=fundamental","pubTime":"2026-01-06 23:05","pubTimestamp":1767711953,"startTime":"0","endTime":"0","summary":"Weight-loss drugmakers' stocks jumped. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up around 2%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c7a5ad1f4c9cc897f075885965193731","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","GPCR","PFE","NVO","RHHBY","AMGN","VKTX"],"gpt_icon":1},{"id":"2594287008","title":"12 Days of Christmas? 12 Stocks That Are Gifts for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287008","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594287008?lang=en_us&edition=fundamental","pubTime":"2025-12-25 15:05","pubTimestamp":1766646309,"startTime":"0","endTime":"0","summary":"It's the holiday season, and what investors would probably like more than some spiked eggnog on Christmas morning are stocks that can be big winners in the new year.Amazon.com doesn't deliver those, though. Still, with the help of Wall Street, it's possible to develop a Santa-like list of nice and naughty names.Barron's  looked at the Russell 1000 group of stocks and used Wall Street ratings and price targets by sector to find presents for any type of investor.Some of the largest Magnificent Seven stocks jumped off the page. Nvidia, Amazon, and Microsoft shares are loved by the Street, with a Buy rating from more than 90% of the analysts covering them. The average Buy-rating ratio for stocks in the Russell 1000 is currently about 58%.Wall Street price targets can typically be read in one of two ways. It is the price an analyst expects a stock to trade at over the coming 12 months, or the price an investor can pay to earn an adequate return in the future.The average gain implied by targ","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"13d44e8d649e7e968597cd411f47871e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1084165304.USD","LU0642271901.SGD","LU2125909759.SGD","LU2191332357.HKD","IE00B3SWFQ91.USD","LU1623119135.USD","LU0788109477.HKD","LU2360106780.USD","LU0210536198.USD","LU0820561909.HKD","LU2491049909.HKD","IE0034235188.USD","LU0444971666.USD","LU0965508806.USD","LU1992135399.USD","LU2097344357.USD","LU0198837287.USD","LU1119994496.HKD","LU2456880835.USD","SGXZ51526630.SGD","IE00BHPRN162.USD","IE00BWXC8680.SGD","BK4527","BK4592","LU2111349929.HKD","LU0868494708.USD","LU1116320737.USD","LU2458330169.SGD","LU1571399168.USD","LU1861127337.USD","LU0868494617.USD","LU2272731782.SGD","LU0889565833.HKD","LU1366333091.USD","LU2413666426.HKD","SG9999015341.SGD","LU0187121727.USD","SG9999015358.SGD","AMZN","LU2413666699.HKD","LU2290526834.HKD","LU2361044865.SGD","IE00BKPKM429.USD","NVDU","IE00BN29S564.USD","LU1989772923.USD","IE00BDCRKT87.USD","IE00B1XK9C88.USD","LU1804176565.USD","2NVD.UK","LU2506951792.HKD","IE0034235295.USD","LU1791710582.SGD","LU1064131342.USD","LU2361045086.USD","LU1868836591.USD","LU0079474960.USD","LU2168564495.EUR","LU1242518931.SGD","LU0029864427.USD","SG9999018865.SGD","LU0234572021.USD","LU1242518857.USD","BK4551","LU1935042488.USD","BK4008","TSLA","LU0345768740.USD","LU2108987350.USD","3NVD.UK","NVDS.UK","NVDY","BK4608","BK4141","LU0965509010.AUD","LU0823434740.USD","BK4532","IE00BJTD4V19.USD","IE00BK4W5M84.HKD","LU1989772840.SGD","LU1548497426.USD","LU2896262040.SGD","LU0061475181.USD","LU1069344957.HKD","LU0345769631.USD","LU0820562030.AUD","LU1720051017.SGD","LU2087621335.USD","LU2322448957.HKD","SG9999002224.SGD","NVD2.UK","IE00BJTD4N35.SGD","LU2242650005.HKD","LU0211328371.USD","IE00B19Z9505.USD","LU0476273544.USD","LU0276348264.USD","IE00B775H168.HKD","LU1145028129.USD","LU0210528500.USD","LU0345769128.USD","LU1066051811.HKD","LU2125909593.SGD","LU2746668461.USD","LU0158827781.USD","IE000W1ABFV2.USD","LU0345768153.USD","LU1674673428.USD","LU2065171311.SGD","LU1699723380.USD","LU0070217475.USD","LU1923623000.USD","IE00BZ1G4Q59.USD","LU2452424414.USD","NVDA","LU0979878070.USD","LU2272731600.USD","IE00BMPRXR70.SGD","LU2249611893.SGD","LU0061474960.USD","LU1720051108.HKD","LU1244550494.USD","LU2491050154.USD","LU0316494557.USD","LU0238689110.USD","LU0823434583.USD","LU2552382132.HKD","LU1868836757.USD","LU0823414478.USD","BK4554","SGXZ31699556.SGD","LU0724617625.USD","LU2125909916.SGD","LU2543165471.USD","LU2083900584.USD","LU0080751232.USD","LU0353189680.USD","LU0158827948.USD","LU0689626769.HKD","LU2023250330.USD","LU2125154778.USD","LU2092937148.SGD","LU0265550946.USD","LU2168564149.EUR","LU2463028550.USD","LU0109392836.USD","LU0310800379.SGD","IE00B4JS1V06.HKD","LU0289960550.SGD","LU2750360641.GBP","BK4550","LU0672654240.SGD","LU1280957306.USD","LU2065169927.USD","LU1496350171.SGD","MSFT","LU2271345857.HKD","LU2756315664.SGD","BK4503","BK4533","LU0683600562.USD","LU1861220033.SGD","LU1868837300.USD","SG9999014880.SGD","LU1633808545.USD","LU1429558221.USD","IE00BZ199S13.USD","LU2065171402.SGD","LU1935042215.USD","LU0354030438.USD","LU0107464264.USD","LU0256863811.USD","LU0053666078.USD","IE000YTNTUN2.SGD","LU0094547139.USD","LU0353189763.USD","SG9999014567.USD","LU2087625088.SGD","LU2294711713.HKD","LU0786609619.USD","LU1803068979.SGD","LU0048584097.USD","LU2211815571.USD","LU0957808578.USD","LU0708995401.HKD","LU1642822529.SGD","SG9999000418.SGD","LU1435385759.SGD","BK4585","IE00BD6J9T35.USD","LU0124676726.USD","LU2430703095.HKD","LU0308772762.SGD","LU0006306889.USD","LU2931357623.SGD","LU2505996509.AUD","LU2471134796.USD","BK4588","LU0289739343.SGD","LU0985320562.USD","LU2552382215.SGD","IE0009356076.USD","LU1791710400.SGD","LU2092627202.USD","LU1674673691.USD","LU0210533765.USD","LU0320765059.SGD","LU0175139822.USD","LU2322448791.USD","LU0061474705.USD","LU1267930730.SGD","LU1116320901.HKD","LU1712237335.SGD","LU1868836914.USD","LU2860962120.EUR","LU0203202063.USD","IE00B4YYXB79.USD","LU0323591593.USD","LU1629891620.HKD","LU0708994859.HKD","LU1316542783.SGD","IE00B3M56506.USD","IE0004086264.USD","HK0000320223.HKD","LU2244417387.USD","LU0265550359.USD","LU0342679015.USD","BK4598","BK4605","LU0942090050.USD","IE00BQXX3C00.GBP","LU2471134952.CNY","IE00BK4W5L77.USD","LU2097344431.USD","IE00BMPRXN33.USD","LU2250418816.HKD","GB00BDT5M118.USD","LU1721428933.USD","LU1267930490.SGD","IE00BYXW3230.USD","LU1821325948.USD","LU2236285917.USD","LU0861579265.USD","LU1935043023.USD","LU2089985449.USD","SG9999014914.USD","LU2286300806.USD","BK4543","SG9999017495.SGD","LU1934455277.USD","LU0444973449.USD","LU0096364046.USD","HK0000306685.HKD","LU1951200564.SGD","NVDD","LU2417539215.USD","LU0310799852.SGD","LU2213496289.HKD","ALK","LU2242649171.HKD","LU2420271590.USD","SNVD.UK","LU0106261372.USD","LU1261432733.SGD","LU0787776722.HKD","LU1989764748.USD","LU2168564222.USD","LU0082616367.USD","LU2403377893.USD","NVDS","LU2023250504.SGD","LU1868837136.USD","LU0077335932.USD","LU2491050071.SGD","LU1815333072.USD","LU2433249047.HKD","LU0354030511.USD","LU1839511570.USD","LU2462157665.USD","IE00BMPRXQ63.HKD","LU0069063385.USD","NVD3.UK","IE000KEQY171.SGD","IE0003U64NQ7.SGD","IE00BDRTCR15.USD","IE0009G5SDU7.USD","IE00BQXX3D17.EUR","IE00B19Z8W00.USD","LU1037948897.HKD","LU2461242641.AUD","AUR","IE0005OL40V9.USD","VKTX","LU0511384066.AUD","LU2264538146.SGD","LU0234570918.USD","LU0823421333.USD","LU1244550221.USD","LU0081259029.USD","LU0157215616.USD","IE00BJLML261.HKD","LU1127390331.HKD","LU0266013472.USD","LU2357125470.USD","SG9999014559.SGD","LU1852331112.SGD","SG9999002232.USD","LU0267386448.USD","RARE","LU2168564065.EUR","BK4614","LU0251132253.USD","LU1066053197.SGD","LU0494093205.USD","LU1992135472.HKD","LU0417517546.SGD","SGXZ99366536.SGD","BK4567","LU1718418525.SGD","LU1951198990.SGD","LU2265009873.SGD","IE0004445015.USD","LU1778281490.HKD","LU0882574139.USD","LU0528227936.USD","LU0823421416.USD","LU1983260115.SGD","SG9999018857.SGD","IE0001KFT4U8.USD","LU2054465674.USD","LU0109391861.USD","LU2430703178.SGD","LU1814569148.SGD","LU2168563687.JPY","LU2750360997.AUD","LU2089284900.SGD","LU0345770308.USD","IE000ITXATA3.USD","LU1861215975.USD","NVD","LU0390134368.USD","BK4548","BK4534","LU0057025933.USD","LU2458330243.SGD","LU2360107168.USD","LU2028103732.USD","LU1934455194.USD","LU1923622614.USD","LU2247934214.USD","LU0072462426.USD","LU2471134879.HKD","LU1037948541.HKD","LU1988902786.USD","SG9999015986.USD","IE00B1BXHZ80.USD","NVDX","LU0289961442.SGD","LU2326559502.SGD","LU1551013425.SGD","LU1244550577.SGD","LU2065170008.USD","LU1934455863.HKD","SG9999004303.SGD","LU2505996681.GBP","LU0557290698.USD","LU0215105999.USD","BK4500","IE00B19Z8X17.USD","SG9999001424.SGD","LU0348723411.USD","SG9999014906.USD","IE00BKVL7J92.USD","LU1815336760.USD","LU0170899867.USD","LU0225283273.USD","LU0689472784.USD","LU2602419157.SGD","IE00B7KXQ091.USD","LU0957791311.USD","LU2473716301.USD","SG9999015952.SGD","TROW","LU1035775433.USD","LU2430703251.USD","BK4529","IE00BQXX3F31.USD","LU2237438978.USD","LU2077746001.SGD","LU2361044949.HKD","LU0211327993.USD","LU1066051225.USD","LU0056508442.USD","SG9999015978.USD","LU0466842654.USD","NVDL","LU1323610961.USD","LU0964807845.USD","BK4581","LU2360032135.SGD","IE00BFSS7M15.SGD","LU2592432038.USD","SG9999014898.SGD","LU1935043536.SGD","LU2125154935.USD","IE00BJJMRY28.SGD","LU1366192091.USD","LU0256863902.USD","LU2106854487.HKD","LU2756315318.SGD","SG9999014575.USD","LU1267930573.SGD","LU0823414551.USD","LU0128525929.USD","IE0034235303.USD","LU1974910355.USD","HK0000306701.USD","BK4612","LU0097036916.USD","LU1551013342.USD","LU0943347566.SGD","SGXZ23171101.USD","LU2272731865.HKD","BK4549","LU1935042991.SGD","IE00B5949003.HKD","BK4587","LU0472753341.HKD","LU2125909247.SGD","LU2487616109.SGD","LU2552382058.USD","LU2237957902.USD","SG9999015945.SGD","LU0820561818.USD","LU2023251221.USD","LU2237957811.SGD","HK0000320264.USD","LU0154236417.USD","SG9999014542.SGD","NVIW.SI","LU2471134523.USD","LU0096362180.USD","LU1989764664.SGD","LU0347712357.USD","LU1496350502.SGD","LU1232071149.USD","LU1914381329.SGD","LU2381873111.SGD","LU0203201768.USD","LU0640476718.USD","LU1066051498.USD","IE0004091025.USD","LU2089283258.USD","LU2357305700.SGD","LU1917777945.USD","LU0965509101.SGD","LU1923622291.USD","LU0127658192.USD","DD","IE00BJJMRX11.SGD","SGXZ81514606.USD","IE0004445239.USD","IE00BFSS8Q28.SGD","IE00BKDWB100.SGD","LU2063271972.USD","QXO","LU2746668974.SGD","LU0719512351.SGD","LU0965509283.SGD","LU0345770993.USD","BK4579","LOAR","LU0274383776.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.028},{"period":"1month","weight":-0.0803},{"period":"3month","weight":-0.2069},{"period":"6month","weight":-0.2198},{"period":"1year","weight":-0.0868},{"period":"ytd","weight":-0.1597}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006749},{"month":2,"riseRate":0.545455,"avgChangeRate":0.207326},{"month":3,"riseRate":0.3,"avgChangeRate":-0.034371},{"month":4,"riseRate":0.5,"avgChangeRate":0.019074},{"month":5,"riseRate":0.272727,"avgChangeRate":0.07927},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.022105},{"month":7,"riseRate":0.545455,"avgChangeRate":0.01621},{"month":8,"riseRate":0.454545,"avgChangeRate":0.012248},{"month":9,"riseRate":0.272727,"avgChangeRate":0.053956},{"month":10,"riseRate":0.363636,"avgChangeRate":0.052351},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.018186},{"month":12,"riseRate":0.545455,"avgChangeRate":0.143438}],"exchange":"NASDAQ","name":"Viking Therapeutics","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics(VKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Viking Therapeutics(VKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Viking Therapeutics,VKTX,Viking Therapeutics股票,Viking Therapeutics股票老虎,Viking Therapeutics股票老虎国际,Viking Therapeutics行情,Viking Therapeutics股票行情,Viking Therapeutics股价,Viking Therapeutics股市,Viking Therapeutics股票价格,Viking Therapeutics股票交易,Viking Therapeutics股票购买,Viking Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics(VKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Viking Therapeutics(VKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}